Evidence map›Paper›PMID 26323022›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2015

Impact of Phosphorus-Based Food Additives on Bone and Mineral Metabolism.

Orlando M Gutiérrez, Alexandra Luzuriaga-McPherson, Yiming Lin, Linda C Gilbert, Shin-Woo Ha, George R Beck

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03841786 (Effect of Phosphorus Additives on the Metabolome in Healthy Adults), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03841786 nacompletednot on this mapstarted 2019, after this paper: background citation

Effect of Phosphorus Additives on the Metabolome in Healthy Adults

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2019 to 2022Enrolled30ConditionsMetabolic Syndrome, Insulin Sensitivity, Cardiovascular DiseasesArmsPhosphorus-supplemented study diet, Control Diet
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017
    Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Supplements for bone health.Archives of endocrinology and metabolism · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. WHEN PHYSIOLOGY MEETS THE BUILT ENVIRONMENT: THE PHOSPHORUS STORY.Transactions of the American Clinical and Climatological Association · 2025
    Review
  17. Phosphorous intake in foods and phosphorus status markers in circulation in the Boston Puerto Rican Health Study.Journal of food composition and analysis : an official publication of the United Nations University, International Network of Food Data Systems · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Orlando M GutiérrezDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
Alexandra Luzuriaga-McPhersonDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
Yiming LinDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
Linda C GilbertDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
Shin-Woo HaDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
George R BeckDivision of Nephrology, Department of Medicine (O.M.G., A.L.-M.), and Department of Epidemiology (O.M.G.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine (Y.L., S.-W.H., G.R.B.), Emory University, Atlanta, Georgia, 30322; The Atlanta Department of Veterans Affairs Medical Center (L.C.G., G.R.B.), Decatur, Georgia 30033; and The Winship Cancer Institute (G.R.B.), Emory University, Atlanta, Georgia 30322.
Emory University · USPediatric Nephrology of Alabama · USUnited States Department of Veterans Affairs · USUniversity of Alabama at Birmingham · US

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
UAB Center for Clinical and Translational Science (CCTS) UL1UL1TR000165 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$9.6M
Inorganic phosphate regulated proliferation, transformation and tumorigenesisR01CA136716 · NCI · EMORY UNIVERSITY · PI BECK, GEORGE R. · 2010 to 2013
$1.2M
Impact of disordered mineral metabolism on stroke and cognitive impairmentR01NS080850 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M · 2012 to 2016
$1.2M
Phosphorus-based Food Additives, Mineral Metabolism and Cardiovascular HealthR03DK095005 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M · 2012 to 2014
$543k
Bio-active Nanoparticles and the stimulation of autophagy for improved bone massI01BX002363 · VA · VETERANS HEALTH ADMINISTRATION · PI BECK, GEORGE R. · 2014 to 2017
–
BLRD VA I01 BX002363NCATS NIH HHS UL1 TR000165NCATS NIH HHS UL1 TR001417NCATS NIH HHS UL1TR00165NCI NIH HHS R01 CA136716NCI NIH HHS R01CA136716NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30DK056336NIDDK NIH HHS P30 DK079626NIDDK NIH HHS P30DK079626NIDDK NIH HHS R03 DK095005NIDDK NIH HHS R03DK095005NINDS NIH HHS R01 NS080850NINDS NIH HHS R01NS080850
6 · The paper itself

Abstract

contextPhosphorus-based food additives can substantially increase total phosphorus intake per day, but the effect of these additives on endocrine factors regulating bone and mineral metabolism is unclear.

objectiveThis study aimed to examine the effect of phosphorus additives on markers of bone and mineral metabolism. Design and Setting, and Participants: This was a feeding study of 10 healthy individuals fed a diet providing ∼1000 mg of phosphorus/d using foods known to be free of phosphorus additives for 1 week (low-additive diet), immediately followed by a diet containing identical food items; however, the foods contained phosphorus additives (additive-enhanced diet). Parallel studies were conducted in animals fed low- (0.2%) and high- (1.8%) phosphorus diets for 5 or 15 weeks.

main outcome measuresThe changes in markers of mineral metabolism after each diet period were measured.

resultsParticipants were 32 ± 8 years old, 30% male, and 70% black. The measured phosphorus content of the additive-enhanced diet was 606 ± 125 mg higher than the low-additive diet (P < .001). After 1 week of the low-additive diet, consuming the additive-enhanced diet for 1 week significantly increased circulating fibroblast growth factor 23 (FGF23), osteopontin, and osteocalcin concentrations by 23, 10, and 11%, respectively, and decreased mean sclerostin concentrations (P < .05 for all). Similarly, high-phosphorus diets in mice significantly increased blood FGF23, osteopontin and osteocalcin, lowered sclerostin, and decreased bone mineral density (P < .05 for all).

conclusionsThe enhanced phosphorus content of processed foods can disturb bone and mineral metabolism in humans. The results of the animal studies suggest that this may compromise bone health.

Indexed as

Adaptor Proteins, Signal TransducingAdultAnimalsBiomarkersBone and BonesBone DensityBone Morphogenetic ProteinsDietFeeding BehaviorFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFood AdditivesGenetic MarkersHumansMaleAdaptor Proteins, Signal TransducingBiomarkersBone Morphogenetic ProteinsFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsFood AdditivesGenetic MarkersMineralsOsteocalcinOsteopontinPhosphorus CompoundsSOST protein, human

Identifiers

PMID26323022
PMCPMC4702463
OpenAlexW2110435733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.